“It seems that the Swedish scientists are on to something,” he told Swedish daily Dagens Nyheter.
Volunteer patients taking part in the experiment in Tanzania, who have been given the new vaccine, have developed both specific immune cells targeting HIV-infiltrated cells in the body, as well as antibodies against HIV and other viral strains contained within the vaccine.
“This is both much unexpected and a very good result. The vaccine is not harmful to the patient and it creates a resistance to the virus,” said Britta Wahren, one of the scientists behind the project.
Despite the good results it is still too early to say whether or not Hivis will give full protection against HIV. The new study will be presented at an Aids Vaccine Conference in Paris on Monday.